SUCCESSFUL CA$4.4m FINANCING FOR ALBERT LABS INC. (CSE: ABRT) TO A LISTING ON THE CANADIAN STOCK EXCHANGE
Chrystal Capital Partners LLP (“Chrystal”), a Mayfair-based corporate finance and investment house, is pleased to announce that it has raised CA$4.4m from its family office and UHNWI network into Albert Labs Inc (“Albert Labs”; CSE:ABRT) which simultaneously listed on the Canadian Securities Exchange. Albert Labs is the first psychedelic company leveraging Real World Evidence Studies to reduce the time and expense necessary to deliver therapies to patients with urgent unmet needs, and accelerate access to psychedelic therapy in hospital settings across the UK & Europe for cancer related anxiety and depression indications initially.
“There is little doubt that mental health and wellness related issues will be one of the largest secular growth sectors over the next decade. Psychedelics have a long and proven track record in being a core solution to multiple mental health issues that affect millions of people annually. Albert Labs is at the forefront of bringing much needed solutions to people with unmet needs and we were delighted to see such a strong response from our investors allowing us to raise the company CA$4.4m into its RTO onto the Canadian Securities Exchange. We look forward to helping finance Albert Labs as it continues to develop much needed and highly effective psychedelic related products, initially in the UK and Europe and ultimately globally.”
“With laboratories in Canada and Portugal, and through our relationships with cancer clinics in the UK such as Christies, we are fully focused on bringing our psilocybin related products to market to provide a much needed solution for millions of patients suffering from cancer related mental health and wellness issues. We will be using Real World Evidence regulatory pathways to accelerate the timelines to providing our novel products to patients and look forward to releasing patient data in due course as we progress an accelerated timeline to a licenced product.”
About Albert Labs
Starting with cancer-related anxiety, depression and existential crisis, Albert Labs will bring psilocybin-assisted therapy to the UK and Europe before expanding globally.
Albert forms collaborations to access existing research experts, clinical infrastructure and patient pools to deliver its psychedelic-assisted therapies. Minimal Capex required vs companies developing novel molecules or clinic settings (i.e. Compass, Field Trip etc.) Working with the largest oncology centre in Europe to drive access to psychedelic assisted therapy.
Albert owns the study data to develop and protect its recognized psilocybin-based therapies. Albert Labs has a particular focus on natural psilocybin cultivation for which we have submitted a patent application. The patent enables Albert Labs to scale their natural mycelium and produce consistent EU GMP psilocybin and the other synergistic actives.
Learn more at https://albertlabs.com/
For further information please contact:
Kingsley Wilson
Investment Partner
kingsley.wilson@chrystalcapital.com
https://www.chrystalcapital.com